ERBB2 and breast carcinoma: ,7 In this direction, several neoadjuvant trials have explored the combination of 2 anti-HER2 drugs (i.e., dual HER2 blockade) with either trastuzumab-lapatinib or trastuzumab-pertuzumab in the absence of cytotoxic therapy.8, 9, 10, 11, 12, 13, 14 Overall, this treatment strategy achieves pCR rates of 20–40% after 4–6 months of therapy.8, 9, 10, 11, 12, 13 However, HER2-positive breast cancer is generally chemosensitive and the rates of pCR in the absence of chemotherapy are lower than in the presence of chemotherapy.12